Approach to lipoprotein management in 2001 National Cholesterol guidelines

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

In 2001 the National Cholesterol Education Program (NCEP) released its Adult Treatment Panel (ATP) III report. This was an evidence-based report that upgraded cholesterol management guidelines. The update was made possible by a series of large, cholesterol-lowering clinical trials. These trials demonstrated strongly the efficacy and safety of cholesterol reduction in both primary and secondary prevention of coronary heart disease (CHD). The major recommendations of the report were several. Low-density lipoprotein (LDL) cholesterol continued to be identified as the major target of cholesterol-lowering therapy. However, more emphasis was given to HDL cholesterol and triglycerides as important targets for management. The concept of CHD risk equivalents was introduced. A CHD risk equivalent represents an absolute risk for future CHD events equal to that in persons with established CHD. Diabetes was identified as a CHD risk equivalent, requiring more intensive LDL-lowering therapy. Finally, the report placed more emphasis on the metabolic syndrome as a major, multiplex risk factor requiring increased clinical attention.

Original languageEnglish (US)
JournalAmerican Journal of Cardiology
Volume90
Issue number8 SUPPL.
StatePublished - Oct 17 2002

Fingerprint

Lipoproteins
Coronary Disease
Cholesterol
Guidelines
Primary Prevention
Secondary Prevention
LDL Lipoproteins
LDL Cholesterol
HDL Cholesterol
Triglycerides
Therapeutics
Clinical Trials
Safety
Education

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Approach to lipoprotein management in 2001 National Cholesterol guidelines. / Grundy, Scott M.

In: American Journal of Cardiology, Vol. 90, No. 8 SUPPL., 17.10.2002.

Research output: Contribution to journalArticle

@article{0f04bfcaffcc481bacf16033f15ce6a9,
title = "Approach to lipoprotein management in 2001 National Cholesterol guidelines",
abstract = "In 2001 the National Cholesterol Education Program (NCEP) released its Adult Treatment Panel (ATP) III report. This was an evidence-based report that upgraded cholesterol management guidelines. The update was made possible by a series of large, cholesterol-lowering clinical trials. These trials demonstrated strongly the efficacy and safety of cholesterol reduction in both primary and secondary prevention of coronary heart disease (CHD). The major recommendations of the report were several. Low-density lipoprotein (LDL) cholesterol continued to be identified as the major target of cholesterol-lowering therapy. However, more emphasis was given to HDL cholesterol and triglycerides as important targets for management. The concept of CHD risk equivalents was introduced. A CHD risk equivalent represents an absolute risk for future CHD events equal to that in persons with established CHD. Diabetes was identified as a CHD risk equivalent, requiring more intensive LDL-lowering therapy. Finally, the report placed more emphasis on the metabolic syndrome as a major, multiplex risk factor requiring increased clinical attention.",
author = "Grundy, {Scott M}",
year = "2002",
month = "10",
day = "17",
language = "English (US)",
volume = "90",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "8 SUPPL.",

}

TY - JOUR

T1 - Approach to lipoprotein management in 2001 National Cholesterol guidelines

AU - Grundy, Scott M

PY - 2002/10/17

Y1 - 2002/10/17

N2 - In 2001 the National Cholesterol Education Program (NCEP) released its Adult Treatment Panel (ATP) III report. This was an evidence-based report that upgraded cholesterol management guidelines. The update was made possible by a series of large, cholesterol-lowering clinical trials. These trials demonstrated strongly the efficacy and safety of cholesterol reduction in both primary and secondary prevention of coronary heart disease (CHD). The major recommendations of the report were several. Low-density lipoprotein (LDL) cholesterol continued to be identified as the major target of cholesterol-lowering therapy. However, more emphasis was given to HDL cholesterol and triglycerides as important targets for management. The concept of CHD risk equivalents was introduced. A CHD risk equivalent represents an absolute risk for future CHD events equal to that in persons with established CHD. Diabetes was identified as a CHD risk equivalent, requiring more intensive LDL-lowering therapy. Finally, the report placed more emphasis on the metabolic syndrome as a major, multiplex risk factor requiring increased clinical attention.

AB - In 2001 the National Cholesterol Education Program (NCEP) released its Adult Treatment Panel (ATP) III report. This was an evidence-based report that upgraded cholesterol management guidelines. The update was made possible by a series of large, cholesterol-lowering clinical trials. These trials demonstrated strongly the efficacy and safety of cholesterol reduction in both primary and secondary prevention of coronary heart disease (CHD). The major recommendations of the report were several. Low-density lipoprotein (LDL) cholesterol continued to be identified as the major target of cholesterol-lowering therapy. However, more emphasis was given to HDL cholesterol and triglycerides as important targets for management. The concept of CHD risk equivalents was introduced. A CHD risk equivalent represents an absolute risk for future CHD events equal to that in persons with established CHD. Diabetes was identified as a CHD risk equivalent, requiring more intensive LDL-lowering therapy. Finally, the report placed more emphasis on the metabolic syndrome as a major, multiplex risk factor requiring increased clinical attention.

UR - http://www.scopus.com/inward/record.url?scp=0037126372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037126372&partnerID=8YFLogxK

M3 - Article

VL - 90

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 8 SUPPL.

ER -